---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-106915"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:46:12.339187+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# TScan Q2 net loss $37M, cash ~$218M funds ops into Q1 2027; heme/solid tumor milestones on track

## Summary
- Q2 2025 revenue $3.1M (vs $0.5M YoY) from Amgen collaboration; R&D spend $32.6M.
- Net loss $37M vs $31.7M in Q2 2024; cash+equivalents+securities $218M (excl. $5M restricted).
- Expects to dose first solid tumor patients with multiplex TCR-T in Q3 2025; initial safety/response data in Q1 2026.
- Plans to initiate registrational trial for TSC-101 in H2 2025 and file IND for TSC-102-A0301 in H2 2025.
- ALL OHA Phase 1 two-year relapse data on TSC-101 to be presented by end of 2025.

## SEC filing metadata
- accession: 0000950170-25-106915
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000095017025106915/0000950170-25-106915-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000095017025106915/tcrx-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-106915
- JSON: https://secwatch.observer/filing/0000950170-25-106915.json
- Plain text: https://secwatch.observer/filing/0000950170-25-106915.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.